Blood marker can predict heart disease risk in type-2 diabetes patients
Measuring a blood marker, copeptin, can successfully predict the risk of heart attacks in people with type-2 diabetes.
List view / Grid view
Measuring a blood marker, copeptin, can successfully predict the risk of heart attacks in people with type-2 diabetes.
In a Phase I clinical trial, heart failure patients treated with patches made from their muscle cells showed improved exercise capacity and heart function after one year. Stem cell patch-based therapy may be a viable heart failure therapy and should be validated in larger clinical trials, researchers conclude.
29 September 2016 | By Niamh Louise Marriott, Digital Content Producer
It is difficult to estimate the global burden of cardiovascular disease in people with diabetes, due to lack of data and standardisation...
8 July 2016 | By Victoria White, Digital Content Producer
Researchers were able to determine that Wars2 plays an important role in supplying sufficient endothelial cells for angiogenesis...
24 February 2016 | By Victoria White
Using a modified version of troponin C, researchers showed it can enhance or therapeutically preserve heart function and cardiovascular performance in mice...
21 January 2016 | By Hans Fliri PhD, Chairman, Cypralis
Here, Dr Hans Fliri, Chairman and CEO of Selcia and Chairman of Cypralis, presents a strong case for targeting mitochondrial cyclophilin D to prevent progression of chronic neurodegenerative diseases...
20 January 2016 | By Victoria White
Mucosis has secured the €3.7 million translational fund award from the Wellcome Trust to progress SynGEM into Phase I and IIa human clinical trials...
14 January 2016 | By Victoria White
Calibr's antibody fusion technology provides a proprietary, modular approach to developing long-acting biotherapeutics based on peptide and protein agonists and antagonists...
6 January 2016 | By Victoria White
Researchers tested the drug, commonly used to treat leukaemia, in zebrafish bred to carry Duchenne muscular dystrophy and recorded a 40% improvement in the condition of the fish...
5 January 2016 | By Victoria White
Renova and Research Development Foundation (RDF) have entered into a worldwide exclusive license agreement for RDF's portfolio of urocortin and stresscopin genes, as well as select peptides and proteins...
22 December 2015 | By Victoria White
The IMI has launched two Calls for proposals that will advance drug development in Ebola, childhood cancers, neurological disorders, and eye disease...
21 December 2015 | By Victoria White
Bayer and CRISPR Therapeutics are to form the joint venture to discover, develop and commercialise new breakthrough therapeutics to cure blood disorders, blindness, and congenital heart disease...
15 December 2015 | By Victoria White
Researchers have shown that the presence or absence of the CAP2 gene causes sudden cardiac death in mice...
15 December 2015 | By Victoria White
The "Takeda-CiRA Joint Programme for iPS Cell Applications" (T-CiRA) will begin research in six core directions to explore clinical applications of stem cells in therapeutic areas including cancer, heart failure and diabetes mellitus...
26 November 2015 | By Victoria White
Venom Knowledge Base summarises the results of 5,117 studies in the medical literature describing the use of venom toxins as painkillers and as treatments for diseases...